According to the article, Gilead is offering the same drug in Egypt "at a 99 percent discount to U.S. prices, or about $900 for a full course of treatment," and "wants to tier its pricing based on a country's per-capita income. So patients in the U.K would pay about $57,000 ...while Germans would pay $66,000 and Americans are paying $84,000."
Inevitably, a black market will develop for this drug, because the arbitrage opportunity is substantial. People who're willing to break the law will buy the drug in Egypt for north of $900 and sell it in the US for a lot less than $90,000.
--
PS. Even though the title of the article is linkbait, and the article itself has little content, I found it worth reading, because I learned something new: pharmaceutical companies are selling drugs in developing countries at a 99% discount (!) to developed-country prices. I knew prices were lower in developing countries, but not that low.